Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lumos Pharma Inc (LUMO)

Lumos Pharma Inc (LUMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lumos Pharma Presents New Data on LUM-201 from Phase 2 Trials for Pediatric Growth Hormone Deficiency at ESPE 2024

Lumos Pharma presented positive Phase 2 trial data for oral LUM-201, showing sustained growth in pediatric patients with hormone deficiency.Quiver AI SummaryLumos Pharma, Inc. has presented new analyses...

LUMO : 4.33 (+0.23%)
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action

LUMO : 4.33 (+0.23%)
Lumos: Q3 Earnings Snapshot

Lumos: Q3 Earnings Snapshot

LUMO : 4.33 (+0.23%)
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024

LUMO : 4.33 (+0.23%)
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)

LUMO : 4.33 (+0.23%)
Lumos: Q2 Earnings Snapshot

Lumos: Q2 Earnings Snapshot

LUMO : 4.33 (+0.23%)
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials...

LUMO : 4.33 (+0.23%)
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will...

LUMO : 4.33 (+0.23%)
Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for...

LUMO : 4.33 (+0.23%)
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA...

LUMO : 4.33 (+0.23%)

Barchart Exclusives

Did More Missiles Move Morning Markets?
Overnight through early Friday morning saw headlines of Russia firing missiles back at Ukraine. Naturally, some of the Missile Markets responded. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar